Se-Hoon Lee Selected Research

Thymic epithelial tumor

1/2020	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
1/2019	Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Se-Hoon Lee Research Topics

Disease

137	Neoplasms (Cancer) 05/2024 - 10/2004
132	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2024 - 11/2003
31	Neoplasm Metastasis (Metastasis) 05/2024 - 08/2004
26	Lung Neoplasms (Lung Cancer) 05/2024 - 11/2003
17	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 01/2009
16	Adenocarcinoma of Lung 04/2024 - 04/2011
14	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2024 - 12/2003
14	Adenocarcinoma 02/2022 - 11/2006
13	Squamous Cell Carcinoma of Head and Neck 11/2023 - 07/2013
13	Glioma (Gliomas) 02/2022 - 12/2009
12	Breast Neoplasms (Breast Cancer) 12/2023 - 04/2007
11	Renal Cell Carcinoma (Grawitz Tumor) 04/2018 - 08/2009
10	Disease Progression 01/2024 - 01/2011
7	Carcinoma (Carcinomatosis) 10/2023 - 08/2004
6	Brain Neoplasms (Brain Tumor) 12/2023 - 02/2011
5	Lymphoma (Lymphomas) 07/2023 - 10/2013
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2020 - 06/2010
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2016 - 07/2006
4	Infections 01/2024 - 02/2004
4	Exanthema (Rash) 04/2019 - 07/2004
4	Neutropenia 01/2019 - 07/2014
4	Stomach Neoplasms (Stomach Cancer) 09/2017 - 12/2005
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2005 - 11/2004
3	Pneumonia (Pneumonitis) 10/2023 - 12/2008
3	Anemia 10/2023 - 08/2016
3	Hyperglycemia 10/2023 - 07/2015
3	Esophageal Neoplasms (Esophageal Cancer) 12/2020 - 08/2004
3	Head and Neck Neoplasms (Head and Neck Cancer) 08/2020 - 01/2015
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2018 - 01/2016
3	Fatigue 01/2018 - 03/2012
3	Nasopharyngeal Carcinoma 12/2017 - 09/2009
3	Adenoid Cystic Carcinoma (Cylindroma) 01/2017 - 08/2015
3	Triple Negative Breast Neoplasms 03/2011 - 11/2007
2	Tertiary Lymphoid Structures 05/2024 - 01/2023
2	Melanoma (Melanoma, Malignant) 03/2024 - 10/2022
2	Thyroid Neoplasms (Thyroid Cancer) 03/2024 - 01/2016
2	Hepatitis 01/2024 - 01/2019
2	Radiation Pneumonitis 12/2023 - 01/2020

Drug/Important Bio-Agent (IBA)

48	ErbB Receptors (EGF Receptor)IBA 01/2024 - 11/2006
47	Tyrosine Kinase InhibitorsIBA 01/2024 - 06/2008
36	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2016
27	Biomarkers (Surrogate Marker)IBA 05/2024 - 09/2011
22	Gefitinib (Iressa)FDA Link 04/2023 - 07/2004
15	PlatinumIBA 01/2024 - 07/2006
15	Cisplatin (Platino)FDA LinkGeneric 07/2022 - 11/2003
14	pembrolizumabIBA 04/2024 - 01/2016
14	Temozolomide (Temodar)FDA LinkGeneric 02/2022 - 07/2011
13	osimertinibIBA 01/2024 - 12/2015
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2023 - 08/2009
10	Docetaxel (Taxotere)FDA Link 10/2023 - 11/2007
10	Anaplastic Lymphoma KinaseIBA 01/2019 - 05/2011
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 07/2006
8	LigandsIBA 04/2024 - 09/2015
8	Sunitinib (Sutent)FDA Link 09/2014 - 08/2009
6	B7-H1 AntigenIBA 01/2024 - 11/2016
6	Proteins (Proteins, Gene)FDA Link 12/2023 - 08/2012
6	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 01/2011
6	Phosphotransferases (Kinase)IBA 10/2023 - 05/2015
6	Pemetrexed (MTA)FDA Link 04/2019 - 06/2010
6	CrizotinibIBA 01/2019 - 06/2012
6	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2016 - 12/2013
6	Fluorouracil (Carac)FDA LinkGeneric 02/2011 - 04/2005
5	RNA (Ribonucleic Acid)IBA 05/2024 - 11/2012
5	Bevacizumab (Avastin)FDA Link 10/2023 - 05/2013
5	human ERBB2 proteinIBA 10/2023 - 09/2011
5	AfatinibIBA 04/2023 - 01/2016
5	Paclitaxel (Taxol)FDA LinkGeneric 12/2020 - 04/2007
5	Gemcitabine FDA Link 01/2015 - 06/2008
4	Cell-Free Nucleic AcidsIBA 02/2024 - 02/2016
4	NivolumabIBA 01/2024 - 01/2019
4	EnzymesIBA 12/2023 - 01/2015
4	durvalumabIBA 10/2023 - 04/2017
4	Circulating Tumor DNAIBA 01/2023 - 01/2017
4	Irinotecan (Camptosar)FDA LinkGeneric 02/2022 - 04/2005
4	Etoposide (VP 16)FDA LinkGeneric 01/2018 - 11/2003
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2016 - 09/2011
4	MethyltransferasesIBA 04/2013 - 08/2009
3	Monoclonal AntibodiesIBA 01/2023 - 09/2017
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 11/2010
3	pazopanib FDA Link 04/2018 - 08/2016
3	alpha-hydroxyglutarateIBA 01/2016 - 12/2013
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2015 - 07/2006
3	taxaneIBA 08/2012 - 06/2008
3	NimustineIBA 07/2011 - 01/2009
3	Leucovorin (Folinic Acid)FDA Link 05/2008 - 04/2005
2	Therapeutic UsesIBA 05/2024 - 04/2023
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2024 - 03/2005
2	N 30IBA 12/2023 - 06/2010

Therapy/Procedure

75	Therapeutics 05/2024 - 11/2003
59	Drug Therapy (Chemotherapy) 05/2024 - 07/2005
27	Radiotherapy 04/2023 - 07/2006
23	Chemoradiotherapy 02/2024 - 12/2003
15	Immunotherapy 05/2024 - 09/2015
10	Neoadjuvant Therapy 01/2019 - 11/2007
8	Aftercare (After-Treatment) 12/2020 - 01/2008
7	Combination Drug Therapy (Combination Chemotherapy) 02/2023 - 09/2004
7	Adjuvant Chemotherapy 01/2018 - 04/2007
6	Induction Chemotherapy 01/2019 - 07/2013
3	Drug Tapering 09/2023 - 12/2014
2	Precision Medicine 05/2024 - 04/2023